WOBURN, Mass.--(BUSINESS WIRE)--Aphios Corporation today announced that it has been awarded Phase II of a Fast Track SBIR grant from the National Institute on Drug Abuse (NIDA), NIH for manufacturing cannabidiol (CBD) from marijuana following current Good Manufacturing Practices (cGMP) for Multiple Sclerosis and other central nervous system (CNS) disorders.
The primary goal of this research program is to develop a process for manufacturing pharmaceutical grade CBD following cGMP of the US FDA for use in clinical trials for Multiple Sclerosis and other CNS disorders by the NIH, Aphios and other researchers. The availability of pharmaceutical-grade CBD and other cannabinoids such as Δ9-THC and CBG, manufactured following cGMP guidelines, will facilitate clinical evaluation by investigators and researchers on MS, childhood epilepsy, and other CNS disorders such as Parkinson’s disease (PD), Alzheimer’s disease (AD), Traumatic Brain Injury (TBI), Post-Traumatic Stress Disorder (PTSD), addiction and glaucoma.
According to Dr. Trevor P. Castor, CEO and Principal Investigator on this grant, “Marijuana, which contains more than 100 cannabinoids, has been used anecdotally for centuries for diverse medical indications. There have been numerous self-reported cases by patients that smoking marijuana alleviates symptomatology, some of which has been confirmed by numerous studies and surveys. Research suggests that some cannabinoids and analogs have potential therapeutic benefits. We thus have indications that both cannabinoids from nature and our endogenous ‘endocannabinoids’ are valuable products and targets for treating some CNS disorders. The cGMP manufacturing of clinical-grade, natural non-psychotropic cannabinoids from marijuana that impact CNS disorders is significant because it will establish safety and efficacy of standardized, non-psychotropic cannabinoids through rigorous clinical trials, providing benefits to thousands of patients.”
About Aphios Corporation
Aphios is an emerging growth, green biotechnology company using environmentally sustainable technologies to improve drug discovery, manufacturing, delivery and safety, and develop therapeutics for the treatment of cancers and supportive care, infectious diseases such as HIV, and CNS disorders such as Alzheimer’s disease, Parkinson’s disease and Multiple Sclerosis.
Research reported in this press release is supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number R44DA038932. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.